Zentralnervöse Nebenwirkungen unter Polychemotherapie bei Patienten mit einem Hodentumor

C. Doehn; H. Büttner; P. Fornara; D. Jocham

doi:10.1055/s-2000-7201

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000007.xml

Share / Bookmark

Facebook Linkedin Weibo

Download PDF

Aktuelle Urol 2000; 31(5): 271-282
DOI: 10.1055/s-2000-7201

ÜBERSICHT

Georg Thieme Verlag Stuttgart · New York

Zentralnervöse Nebenwirkungen unter Polychemotherapie bei Patienten mit einem Hodentumor

Central Nervous Events Related to Chemotherapy in Patients with a Germ-Cell TumorC. Doehn, H. Büttner, P. Fornara, D. Jocham

Klinik und Poliklinik für Urologie, Medizinische Universität zu Lübeck

Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at

Abstract
Full Text
References

Buy Article Permissions and Reprints

Zusammenfassung

Zu den Nebenwirkungen der cisplatinbasierten Polychemotherapie gehören in seltenen Fällen auch vaskuläre Ereignisse wie Thrombosen, Embolien sowie Myokard- oder Hirninfarkte. Weiterhin sind zentralnervöse Nebenwirkungen zytostatischer Medikamente wie Hemiparese, epileptischer Anfall bis hin zum Koma beschrieben worden. In der vorliegenden Arbeit wird eine Übersicht zur verfügbaren Literatur zentralnervöser Nebenwirkungen unter Polychemotherapie bei Patienten mit einem Hodentumor gegeben. Dieser Aspekt muss insbesondere auch bei der Aufklärung des Patienten Berücksichtigung finden. Dies ist um so wichtiger, als bei zentralnervösen Komplikationen potenziell letale Gefahren für den Patienten drohen.

Abstract

The complications related to cisplatin-based chemotherapy include vascular events such as thrombosis and myocardial or cerebral infarction. Additionally, central nervous side effects like hemiparesis, status epilepticus and coma have been reported. This review provides an overview of the central nervous side effects during or after chemotherapy for germ-cell tumor. This aspect must be also mentioned in the informed consent for chemotherapy since these side effects are potentially lethal.

Key words

Germ-cell tumor - Chemotherapy - Cisplatin - Central nervous symptoms - Cerebrovascular event - Basilar artery thrombosis - Status epilepticus

Literatur

1 Devesa S S, Blot W J, Stone B J, Miller B A, Tarone R E, Fraumeni Jr J F. Recent cancer trends in the United States. J Natl Cancer Inst. 1995; 87 175-182

PubMed Search in Google Scholar
2 Bosl G J, Motzer R J. Testicular germ-cell cancer. N Engl J Med. 1997; 337 242-253

Crossref PubMed Search in Google Scholar
3 Kinkade S. Testicular cancer. Am Fam Phys. 1999; 59 2539-2544

PubMed Search in Google Scholar
4 Weißbach L, Bussar-Maatz R. Pathogenese, Diagnostik und Therapie von Hodentumoren. Urologe A. 1996; 35 163-172

PubMed Search in Google Scholar
5 Landis S H, Murray T, Bolden S, Wingo P A. Cancer statistics, 1998. CA Cancer J Clin. 1998; 48 6-29

Crossref PubMed Search in Google Scholar
6 McKiernan J M, Goluboff E T, Liberson G L, Golden R, Fisch H. Rising risk of testicular cancer by birth cohort in the United States form 1973 to 1995. J Urol. 1999; 162 361-363

PubMed Search in Google Scholar
7 Osterlind A. Diverging trends in incidence and mortality of testicular cancer in Denmark, 1943 - 1982. Br J Cancer. 1986; 53 501-505

PubMed Search in Google Scholar
8 Richie J P. Detection and treatment of testicular cancer. CA Cancer J Clin. 1993; 43 151-175

PubMed Search in Google Scholar
9 Nicholson P W, Harland S J. Inheritance and testicular cancer. Br J Cancer. 1995; 71 421-426

PubMed Search in Google Scholar
10 Benson Jr R C, Beard C M, Kelalis P P, Kurland L T. Malignant potential of the cryptorchid testis. Mayo Clin Proc. 1991; 66 372-378

PubMed Search in Google Scholar
11 Buetow S A. Epidemiology of testicular cancer. Epidemiol Rev. 1995; 17 433-449

PubMed Search in Google Scholar
12 Møller H, Skakkebæk N E. Risks of testicular cancer and cryptorchidism in relation to socio-economic status and related factors: case-control studies in Denmark. Int J Cancer. 1996; 66 287-293

Crossref PubMed Search in Google Scholar
13 Swerdlow A J, Higgins C D, Pike M C. Risk of testicular cancer in cohort of boys with cryptorchidism. BMJ. 1997; 314 1507-1511

PubMed Search in Google Scholar
14 Dieckmann K P, Pichlmeier U. The prevalence of familial testicular cancer: an analysis of two patient populations and a review of the literature. Cancer. 1997; 80 1954-1960

Crossref PubMed Search in Google Scholar
15 Richie J P. Neoplasms of the testis. In: Walsh PC, Retik AB, Vaughan Jr ED, Wein AJ, eds Campbell's Urology, 7th Edition Philadelphia: WB Saunders 1998: 2411-2452

Search in Google Scholar
16 International Germ Cell Cancer Collaborative Group . International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997; 15 594-603

Crossref PubMed Search in Google Scholar
17 Bredael J J, Vugrin D, Whitmore Jr W F. Autopsy findings in 154 patients with germ cell tumors of the testis. Cancer. 1982; 50 548-551

PubMed Search in Google Scholar
18 Bower M, Newlands E S, Holden L, Rustin G J, Begent R H. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol. 1997; 8 477-483

Crossref PubMed Search in Google Scholar
19 Sonneveld D JA, Hoekstra H J, van der Graaf W TA, Sluiter W J, Schrafford Koops H, Sleijfer D T. The changing distribution of stage in nonseminomatous testicular germ cell tumours, from 1977 to 1996. BJU International. 1999; 84 68-74

Crossref PubMed Search in Google Scholar
20 Leitlinien zur Therapie von Hodentumoren. Urologe A. 1999; 38 201-207

Crossref PubMed Search in Google Scholar
21 Aareleid T, Sant M, Hedelin G. and the Euro Care Group . Improved survival for patients with testicular cancer in Europe since 1978. Eur J Cancer. 1998; 34 2236-2240

Crossref PubMed Search in Google Scholar
22 Einhorn L H, Donohue J P. Advanced testicular cancer: update for urologists. J Urol. 1998; 160 1964-1969

PubMed Search in Google Scholar
23 Gerl A, Sauer H, Liedl B, Hiddemann W. The therapy of testicular tumors 2 decades after the introduction of cisplatin. Dtsch Med Wochenschr. 2000; 125 327-334

PubMed Search in Google Scholar
24 Doll D C, Yarbro J W. Vascular toxicity associated with antineoplastic agents. Sem Oncol. 1992; 19 580-596

PubMed Search in Google Scholar
25 Gerl A. Vascular toxicity associated with chemotherapy for testicular cancer. Anti-Cancer Drugs. 1994; 5 607-614

PubMed Search in Google Scholar
26 Einhorn L H, Donohue J P. Cisdiamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977; 87 293-298

Crossref PubMed Search in Google Scholar
27 Williams S D, Birch R, Einhorn L H, Irwin L, Greco F A, Loehrer P J. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposid. N Engl J Med. 1987; 316 1435-1440

Crossref PubMed Search in Google Scholar
28 Weise J, Köhler G, Müller J. Zur Klinik der ifosfamidinduzierten Enzephalopathie. Tumordiagn Ther. 1997; 18 129-132

PubMed Search in Google Scholar
29 Brennecke H J, Weinknecht S, Finck G A, Mitlehner W, Weissbach L. Rare metabolic and cerebral complications after polychemotherapy of a testicular cancer. Urologe A. 1994; 33 484-486

PubMed Search in Google Scholar
30 Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 1965; 205 698-699

Crossref PubMed Search in Google Scholar
31 Zeller W J. Platin-Analoga. In: Zeller WJ, zur Hausen H, eds Onkologie Landsberg/Lech: ecomed 1995: IV-3.1-IV-3.16

Search in Google Scholar
32 Chabner B A, Allegra C J, Curt G A, Calabresi P. Antineoplastic agents. In: Hardman JG, Gilman AG, Limbird LE, eds Goodman & Gilman's The pharmacological basis of therapeutics, 9th Edition New York: McGraw-Hill 1996: 1233-1287

Search in Google Scholar
33 Takano S, Saitoh M, Ohbu M, Miyasaka Y, Yada K, Takagi H. Brain metastasis of testicular yolk sac tumor with massive hemorrhage: case report. No Shinkei Geka. 1993; 21 533-537

PubMed Search in Google Scholar
34 Doll D C, List A F, Greco F A, Hainsworth J D, Hande K R, Johnson D H. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986; 105 48-51

PubMed Search in Google Scholar
35 Wengs W J, Talwar D, Bernard J. Ifosfamide-induced nonconvulsive status epilepticus. Arch Neurol. 1993; 50 1104-1105

PubMed Search in Google Scholar
36 Bhardwaj A, Badesha P S. Ifosfamide-induced nonconvulsive status epilepticus. Ann Pharmacother. 1995; 29 1237-1239

PubMed Search in Google Scholar
37 Seegenschmiedt M H. Nebenwirkungen der Krebsbehandlung - Klassifikation und Dokumentation. In: Zeller WJ, zur Hausen H, eds Onkologie Landsberg/Lech: ecomed 1995: VII-5

Search in Google Scholar
38 Doehn C, Büttner H, Fornara P, Jocham D. Fatal basilar artery thrombosis after chemotherapy for testicular cancer. Urol Int. 2000; 65 43-45

PubMed Search in Google Scholar
39 Sarasin F P, Eckman M H. Management and prevention of thrombembolic events in patients with cancer-related hypercogulable states: a risky business. J Gen Intern Med. 1993; 8 476-486

PubMed Search in Google Scholar
40 Piccioli A, Prandoni P, Ewenstein B M, Goldhaber S Z. Cancer and venous thromboembolism. Am Heart J. 1996; 132 850-855

Crossref PubMed Search in Google Scholar
41 Rosenberg R D, Aird W C. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med. 1999; 340 1555-1564

Crossref PubMed Search in Google Scholar
42 Shlebak A A, Smith D B. Incidence of objectively diagnosed thrombembolic disease in cancer patients undergoing cytotoxic chemotherapy and/or hormonal therapy. Cancer Chemother Pharmacol. 1997; 39 462-466

Crossref PubMed Search in Google Scholar
43 Lemmers N WM, Gels M E, Sleijfer D T, Plukker J T, van der Graaf W TA, de langen Z J, Droste J HJ, Schraffordt Koops H, Hoekstra H J. Complications with venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy. J Clin Oncol. 1996; 14 2916-2922

PubMed Search in Google Scholar
44 Turlapaty P D, Altura B M. Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science. 1980; 208 198-200

Crossref PubMed Search in Google Scholar
45 Rosenfeld C S, Broder L E. Cisplatin-induced autonomic neuropathy. Cancer Treat Rep. 1984; 68 659-660

PubMed Search in Google Scholar
46 Roca E, Bruera E, Politi P M, Barugel M, Cedaro L, Carraro S, Chacon R D. Vinca alkaloid-induced cardiovascular autonomic neuro-pathy. Cancer Treat Rep. 1985; 69 149-151

PubMed Search in Google Scholar
47 Fossa S D, Aass N, Kaalhus O, Klepp O, Tveter K. Long-term survival and morbidity in patients with metastatic malignant germ cell tumours treated with cisplatin-based combination chemotherapy. Cancer. 1986; 58 2600-2605

PubMed Search in Google Scholar
48 von Tempelhoff G F, Niemann F, Schneider D M, Kirkpatrick C J, Hommel G, Heilmann L. Blood rheology during chemotherapy in patients with ovarian cancer. Throm Res. 1998; 90 73-82

PubMed Search in Google Scholar
49 Donati M B. Cancer and thrombosis: from phlegmasia alba dolens to transgenic mice. Throm Haemostas. 1995; 74 278-281

PubMed Search in Google Scholar
50 Vogelzang N J, Bosl G J, Johnson K, Kennedy B J. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981; 95 288-292

PubMed Search in Google Scholar
51 Berger C C, Boekemeyer C, Schneider M, Kuczyk M A, Schmoll H J. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer. 1995; 31A 2229-2238

PubMed Search in Google Scholar
52 Jakob A, Kollmannsberger C, Kanz L, Bokemeyer C. Spättoxizität nach Chemotherapie maligner Hodentumoren. Urologe A. 1998; 37 635-647

Crossref PubMed Search in Google Scholar
53 Licciardello J T, Moake J L, Rudy C K, Karp D D, Hong W K. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology. 1985; 42 296-300

PubMed Search in Google Scholar
54 Samuels B L, Vogelzang N J, Kennedy B J. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol. 1987; 19 253-256

PubMed Search in Google Scholar
55 Gerl A, Clemm C, Wilmanns W. Acute cerebrovascular event after cisplatin-based chemotherapy for testicular cancer. Lancet. 1991; 338 385-386

PubMed Search in Google Scholar
56 Gerl A, Clemm C, Schleuning M, Wilmanns W. Fatal cerebrovascular accident associated with chemotherapy for testicular cancer. Eur J Cancer. 1993; 29A 1220-1221

PubMed Search in Google Scholar
57 Icli F, Karaoguz H, Dincol D, Demikazik A, Günel N, Karaoguz R, Üner A. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 1993; 72 587-593

Search in Google Scholar
58 Coates A S, Childs A, Cox K, Forsyth C, Joshua D E, McNeil E, Grygiel J J. Severe vascular adverse effects with thrombocytopenia and renal failure following emetgenic chemotherapy and ondansetron. Ann Oncol. 1992; 3 719-722

PubMed Search in Google Scholar
59 Cantwell B MJ, Mannix K A, Roberts J T, Ghani S E, Harris A L. Thrombembolic events during combination chemotherapy for germ cell malignancy. Lancet. 1988; II 1086-1087

PubMed Search in Google Scholar
60 Cullen M H, Stenning S P, Parkinson M C, Fossa S D, Kaye S B, Horwich A H, Harland S J, Williams M V, Jakes R. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a medical research council report. J Clin Oncol. 1996; 14 1106-1113

Crossref PubMed Search in Google Scholar
61 Fossa S D, Droz J P, Stoter G, Kaye S B, Vermeylen K, Sylvester R. Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group. Br J Cancer. 1995; 71 619-624

PubMed Search in Google Scholar
62 Nichols C R, Roth B J, Williams S D, Gill I, Muggia F M, Stablein D M, Weiss R B, Einhorn L H. No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol. 1992; 10 760-765

Crossref PubMed Search in Google Scholar
63 Aeschlimann C, Kupfer A, Schefer H, Cerny T. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metab Dispos. 1998; 26 883-890

PubMed Search in Google Scholar
64 Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken J B. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 1999; 82 291-294

PubMed Search in Google Scholar
65 Kellner O, Dempke W, Schmoll H J. Glukose-Infusionen - eine mögliche effektive Therapieoption bei der Ifosfamid-induzierten Enzephalopathie. Dtsch Med Wschr. 1999; 124 1086

PubMed Search in Google Scholar
66 Büttner H, Pottek T, Hartmann M. ZNS-Metastasen von Hodentumoren. Urologe A. 1995; S114

PubMed Search in Google Scholar
67 Bamberg M, Schmoll H J, Weißbach L. Diagnostik und Therapie von Hodentumoren. Dt Ärztebl. 1997; 94 A2742-2748

PubMed Search in Google Scholar
68 Nussbaum E S, Djalilan H R, Cho K H, Hall W A. Brain Metastases. Histology, Multiplicity, Surgery, and Survival. Cancer. 1996; 78 1781-1788

Crossref PubMed Search in Google Scholar
69 Logothetis C J, Samuels M L, Trindade A. The management of brain metastasis in germ cell tumors. Cancer. 1982; 49 12-18

PubMed Search in Google Scholar
70 Mahalati K, Bilen C Y, Ozen H, Aki F T, Kendi S. The management of brain metastasis in nonseminomatous germ cell tumours. BJU Int. 1999; 83 457-461

Crossref PubMed Search in Google Scholar
71 Fossa S D, Bokemeyer C, Gerl A, Culine S, Jones W G, Mead G M, Germa-Luch J R, Pont J, Schmoll H J, Tjuladin S. Treatment outcome of patients with brain metastasis from malignant germ cell tumors. Cancer. 1999; 85 988-997

Crossref PubMed Search in Google Scholar

Dr. med C Doehn

Oberarzt der Klinik und Poliklinik für Urologie, Medizinische Universität zu Lübeck

Ratzeburger Allee 160 23538 Lübeck

Email: E-mail: doehn@medinf.mu-luebeck.de